News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Idera Pharmaceuticals, Inc. (IDRA) And Collaborators Publish Promising Preclinical Data Targeting Microrna With Gene Silencing Oligonucleotide Technology



8/6/2014 10:46:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced the publication of promising preclinical data demonstrating the application of the Company’s novel Gene Silencing Oligonucleotides (GSOs) to inhibit microRNAs implicated in neovascularization, a process that involves the proliferation of blood vessels in tissue and is crucial for recovery following cardiovascular events. The studies were conducted by Professor Paul Quax, Ph.D., and Yaël Nossent, Ph.D., of the Department of Surgery, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center in the Netherlands in collaboration with Idera. The paper, entitled Inhibition of 14q32 microRNAs miR-329, miR-487b, miR-494 and miR-495 Increases Neovascularization and Blood Flow Recovery after Ischemia, appears in the current online edition of Circulation Research.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES